PLYMOUTH MEETING, Pa., Nov. 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences:
Piper Sandler 37th Annual Healthcare Conference (New York, NY)
Date: Tuesday, December 2
Time: 8:30-8:55 AM ET
Format: Fireside Chat
Webcast: https://bit.ly/44af19l (live webcast and replay available for 90 days after the event)
Oppenheimer Movers in Rare Disease Summit (New York, NY)
Date: Thursday, December 11
Time: 12:05-12:25 PM ET
Format: Panel - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts
Members of INOVIO's management team will also be conducting one-on-one meetings with investors during these conferences.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505, This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$1.78 |
| Daily Change: | 0.02 1.14 |
| Daily Volume: | 896,945 |
| Market Cap: | US$122.290M |
November 10, 2025 November 10, 2025 November 03, 2025 October 21, 2025 August 26, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load